A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drugs ability to lower brain fluid pressure is the key, potentially opening a completely new way to treat migraines. The effects were fast, sustained, and came with only mild side effects.

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.1

Researchers at the Headache Center of the University of Naples “Federico II” ...

An international scientific collaboration has developed a novel nanomaterial to efficiently harvest clean drinking water from water vapor in the air. The nanomaterial can hold more than three times its weight in water and can achieve this far quicker than existing commercial technologies, features that enable its potential in direct applications for producing potable water from the air.

The collaboration is led by the Australian Research Council Center of Excellence for Carbon Science and Innovation (ARC COE-CSI) UNSW Associate Professor Rakesh Joshi and Nobel Laureate Professor Sir Kostya Novoselov. Prof Joshi is based at the School of Materials Science and Engineering, University of New South Wales (UNSW). Prof Novoselov is based at the National University of Singapore.

A Unit...

Identifying the formation period of planetary systems, such as our solar system, could be the beginning of the journey to discover the origin of life. The key to this is the unique substructures found in protoplanetary disks—the sites of planet formation.

A protoplanetary disk is composed of low-temperat...

People with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) have significant differences in their blood compared with healthy individuals, a new study reveals, suggesting a path toward more reliable diagnosis of the long-term debilitating illness. The paper is published in the journal EMBO Molecular Medicine.

The largest ever biological study of ME/CFS has identified consistent blood differences associated with chronic inflammation, insulin resistance, and liver disease.

Significantly, the results were mostly unaffected by patients’ activity levels, as low activity levels can sometimes hide the biological signs of illness, experts say.

The volume and cons...